News: EGFR Resisters Lung Cancer Group

Research Treatments

Stephen Liu, MD, Discusses MARIPOSA Overall Survival Data

*February 2025* In this video, Stephen Liu, MD, of the Georgetown University School of Medicine and Georgetown's Lombardi Comprehensive Cancer Center in Washington, DC, joined Lung Cancers Today to discuss the recent announcement that the phase 3 MARIPOSA trial met its final pre-specified secondary endpoint of overall survival (OS). The…

laurabbook@gmail.comMay 16, 2025

Advocacy

Getting Started in Lung Cancer Advocacy

*February 2025* The lung cancer community has a dire need for more advocates in order for us (both survivors and caregivers) to have more voice and involvement in research projects, clinical trials, and government research funding. Before you make the deep dive into advocacy, here are some networks and recorded…

laurabbook@gmail.comMay 16, 2025

Coping With Cancer Stories

I Lost My Mom and Dad to Lung Cancer—Now I Have It

*February 2025* Diagnosed with lung cancer at just 39 years old, EGFR Resisters co-founder Jill Feldman recounts how her advocacy efforts before her diagnosis prepared her for the battle ahead. Losing both parents and other close family members to lung cancer, Jill feared for her own children and worked tirelessly…

laurabbook@gmail.comMay 16, 2025

Coping With Cancer Stories

Member Spotlight: Maggie McCloskey

*February 2025* Written by Karen LeBonte As Maggie McCloskey celebrated her 60th birthday in May, she told herself, “2021 is going to be the best year of my life!” But between May and September of that year, a slow cascade of puzzling health events began to test her certainty.…

laurabbook@gmail.comMay 16, 2025

EGFR Resisters Announcements/Updates Research Treatments

2024 EGFR Resisters Research Summit Wrap-up Video

*December 2025* The EGFR Resisters and CEC Oncology just held the sixth annual EGFR Resisters Research Summit December 12th and 13th in Louisville, Kentucky. We brought together young investigators from all across the country who are doing work related to EGFR positive lung cancer. And as in the past, we…

laurabbook@gmail.comMay 16, 2025

EGFR Resisters Announcements/Updates

Big News! Bigger Steps! Bold Action! EGFR Resisters Becoming a 501c3 Non-Profit

*January 2025* Dear Friends and Colleagues, As we welcome a new year, we are thrilled to announce that EGFR Resisters is becoming an independent 501(c)(3) non-profit organization! As an independent organization, we are committed to providing you with the opportunities and resources you have come to expect and much, much…

laurabbook@gmail.comJanuary 6, 2025

Research

2021 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Awards Update

*January 2025* 2021 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Award – Dr. Christine Lovly progress update Dr. Christine Lovly from Vanderbilt University is studying how EGFR+ NSCLC cells become resistant to osimertinib, a tyrosine kinase inhibitor currently used as the first treatment option for EGFR+ lung cancer. Specifically, her…

laurabbook@gmail.comJanuary 6, 2025

Research

2023 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Award Year 1 Progress Update

*January 2025* Drug-tolerant persister cells (DTPCs) are cancer cells that survive drug treatment such as tyrosine kinase inhibitors. These cells are a key reason why EGFR-positive NSCLC (EGFR+ NSCLC) can come back after treatment. 2023 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Awardees are studying how to target DTPCs. Dr.…

laurabbook@gmail.comJanuary 6, 2025

Research Treatments

How Biomarker Testing Could Continue to Evolve in NSCLC

*November 2024* In this video, Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss the next steps for biomarker testing in NSCLC. Watch here.

laurabbook@gmail.comDecember 21, 2024

Research Treatments

Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC

*November 2024* Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses de novo vs acquired resistance alterations in HER2-positive non–small cell lung cancer (NSCLC). In HER2-positive NSCLC, alterations can be broadly categorized as either de novo mutations or acquired resistance mutations, Girard begins. De novo mutations…

laurabbook@gmail.comDecember 21, 2024

Recent News & Research

Stephen Liu, MD, Discusses MARIPOSA Overall Survival Data

Getting Started in Lung Cancer Advocacy

I Lost My Mom and Dad to Lung Cancer—Now I Have It

Member Spotlight: Maggie McCloskey

2024 EGFR Resisters Research Summit Wrap-up Video

Big News! Bigger Steps! Bold Action! EGFR Resisters Becoming a 501c3 Non-Profit

2021 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Awards Update

2023 EGFR Resisters/LUNGevity Foundation EGFR-positive Lung Cancer Research Award Year 1 Progress Update

How Biomarker Testing Could Continue to Evolve in NSCLC

Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC

GIVE TODAY

Categories

STAY CONNECTED

You Might Like

BECOME A MEMBER

WHO WE ARE

PROJECTS

ALLIANCES & RESOURCES